An efficient cell selection method is crucial to deliver consistent autologous therapy products when the starting material received is highly variable. Whilst a variety of technologies are being adopted in the industry, there are few GMP-compliant options, and these technologies are often manual, semi-automated, and lack commercial viability. In this article, our experts share insights on obtaining highly purified cells using magnetically active cell selection in a flexible, closed manufacturing system. In addition, transitioning manual cell therapy production to scalable automated processes is discussed.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center